Prostate cancer remains a major health care problem worldwide. Although most current therapies against this disease are designed to target the tumor cells themselves, the surrounding microenvironment plays a leading role in enabling the growth and dissemination of the tumor. Using a fully immunocompetent murine model, our results reveal how stromal conditioning with hemin, a wellknown inducer of Heme Oxygenase-1 (HO-1), limits prostate cancer development by targeting both tumor vascularization and the cytotoxic T cell responses. Taken altogether, these data showcase a novel function of an already human-used drug as a means to boost the endogenous anti-tumor response.
Introduction
Prostate cancer (PCa) is the second most common cancer in men worldwide (1) . Although most current therapies against this disease are designed to target the tumor cells, the surrounding microenvironment plays a leading role in enabling tumor development (2) . Novel cancer therapies should consider the crosstalk between epithelial and stromal compartments, which has been reported to promote tumor progression by remodeling the extracellular matrix to enhance invasion and angiogenesis, releasing soluble factors and disarming the anti-tumor immune surveillance (3) . Understanding the competing interactions between the several pro-and anti-tumorigenic components that shape the complex milieu of the tumor microenvironment, could lead to more integral approaches for cancer treatment (4) .
Chronic inflammation has been associated with a high cancer incidence (5) , providing clear evidence that a deregulated microenvironment affects tumorigenesis. An inflammatory setting fosters tumor progression through a wide range of mechanisms and represents a decisive factor in its evolution (6, 7) .
Of note, inflammation-driven anatomical expansion and increased activation of the remodelled microvascular bed promotes angiogenesis and further influx of immune cells, which become codependent processes (8) .
Several molecular pathways have been linked to cancer and inflammation (9) . In particular, the enzyme Heme Oxygenase-1 (HO-1) is part of an endogenous defence system implicated in the homeostatic response (10, 11) . The intrinsic effect of HO-1 on tumor cells in different cancer models has been extensively addressed (12, 13) . Furthermore, data are available from a wide spectrum of physiopathological conditions that link HO-1 to modulation of angiogenesis and the immune function, two hallmarks of cancer (7) .
In PCa, we have demonstrated that HO-1-over-expressing human xenografts generated in nude mice show impaired growth (14) and angiogenesis (15) and that this protein modifies the bone 
Real-time reverse transcription-PCR. Transcriptional profile was analyzed in T-C1 tumor samples
and lymph node samples, as previously described (23). Primers are listed in Table S1 . Human PPIA, murine Rplp0, and bovine GAPDH were used as internal reference genes.
Histological analysis. Sections obtained from paraffin-embedded tissues were stained according to
Masson's trichrome technique or subjected to immunohistochemistry (IHC), as previously described (14, 23) , using anti-HO-1 (ab13243, abcam), anti-Gal-1 (H-45, Santa Cruz Biotechnology, Inc.), and anti-CD31 (D8V9E, Cell Signaling) antibodies. Blinded qualitative studies were carried out by a pathologist (RPM).
PCa patient-derived xenografts (PDXs) and tissue microarray (TMA) technology. PDXs were generated at MD Anderson Cancer Center (24) to prepare the TMA (n=50). IHC was carried out and
Research. blinded semi-quantitative studies were performed (RPM): 0, no staining; 1, 2 and 3, low, mild, and high staining, respectively. Scores of individual blokes corresponding to the same PDX were averaged.
Tubulogenesis assay. 80%-confluent T-C1 cells were cultured for 24h in a 1:5 diluted growth media.
Conditioned-media (CM) was harvested and filtered. 60μl of growth factor-reduced Matrigel was plated in a 96-well plate and incubated at 37°C for 15min. 12.5×10 3 hemin-treated (50μM, 8h) or control HUVEC were plated on the Matrigel in the presence of control or T-C1-derived CM. Positive control wells were seeded in EGM-2 medium. Endothelial tube formation was evaluated after 18h. Five fields per well were photographed. AdobePhotoshop-processed photographs were evaluated using the NIH ImageJ Angiogenesis Analyzer Plug-in.
Apoptosis assay. BAEC were treated with hemin (50μM, 8h), washed and subsequently cultured for 16h in a 1:5 diluted growth media containing recombinant Gal-1 (25) (0; 2.25; 4.5; and 9μM). Detached and adherent cells were photographed, harvested (TripLE Express, ThermoFisher) and stained with FITC-Annexin-V (Apoptosis Detection kit, BD Pharmingen) and propidium iodine (Sigma), followed by flow cytometry.
Wound healing assay. HUVEC were treated with hemin (50μM, 8h), washed and subsequently cultured for 24h in a 1:5 diluted growth media. CM was harvested and filtered. Confluent T-C1 cells were washed and serum-starved for 8h. A 1-mm wide scratch was made across the cell layer and, after washing with serum-free medium twice, hemin-treated or control HUVEC CM was added, and plates were photographed immediately and after incubation (12, 24, 48h) at the identical location of initial image. Wound area was quantified using NIH ImageJ.
Tumor-to-endothelium adhesion assay. 80% confluent HUVEC were treated with hemin (50μM, 8h) and subsequently washed. 3×10 4 CFSE-labeled T-C1 cells (2.5µM, 5min, 1×10 6 cells/ml in PBS 1%
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Results

Hemin conditioning impairs PCa development
Given the scarce PCa pre-clinical models available allowing assessment of the whole tumor microenvironment, we used a syngeneic model based on the subcutaneous injection of T-C1 cells into C57BL/6 mice, previously standardized in our laboratory (27) Figure 2C ) and the number of master segments and tube joints in this experimental condition ( Figure S1B) . Importantly, the tube network was not hindered both in complete growth media and in the absence of T-C1-derived CM, confirming HUVEC viability is not significantly affected by hemin pre-treatment. To evaluate the role of Gal-1, we carried out an apoptosis assay in the presence of the recombinant lectin. Whilst control cells did not show Gal-1-induced apoptosis, hemintreated endothelial cells were significantly more susceptible to cell death in a Gal-1 dose-dependent fashion ( Figure 2D ). Of note, hemin-treated cells did not show any significant differences in terms of basal cell death when compared to control cells. The increase in endothelial cell death was further supported by a significant decrease in CD146 mRNA levels ( Figure S2 ), a co-receptor for VEGFR-2 and a decoy receptor for Gal-1 (29, 30) . We next studied whether hemin conditioning influences the crosstalk between tumor and endothelial cells. T-C1 cell motility was significantly impaired when a wound-healing assay was performed in the presence of hemin pre-treated HUVEC CM ( Figure 2E ).
Tumor cell adhesion to endothelial cells was severely reduced when HUVEC were pre-treated with hemin ( Figure 2F ). We ruled out there were hemin traces in the CM by assessing HMOX1 mRNA expression levels in T-C1 that had been exposed, and detected no significant differences (data not shown). Collectively, these findings suggest that hemin conditioning remodels the endothelial compartment and negatively regulates interactions between endothelial and tumor cells. To assess whether hemin pre-treatment is implicated in tumor neovascularization in vivo, we performed a Matrigel plug assay. C57BL/6 mice (n=5) were subjected to our hemin conditioning protocol before being injected with T-C1 cells in Matrigel. Control mice (n=5) were injected with saline-containing Matrigel.
After 5 days, plugs were harvested and hemoglobin content was determined. In keeping with our in vitro findings, hemin pre-treatment significantly inhibited vascularization in vivo ( Figure 2G ). In summary, hemin conditioning impacts upon the angiogenic process, probably accounting for tumor on the day that mice would have been transferred with the mix (Figure 3G) . The left panel of Figure 3H shows representative results, where the relative frequencies between peptide-pulsed target cells and control cells were used as readouts of specific killing. The frequency of CFSE dim-OVA cells was reduced to a greater extent in hemin-treated mice compared to control littermates. OVA-specific cytotoxicity was significantly enhanced when transferred mice were subcutaneously treated with hemin prior to challenge with OVA-loaded cells ( Figure 3H, right panel) . We next sought to determine whether hemin boosts antigen-specific cytotoxicity in vivo if OT-1 lymph node cells were treated ex vivo prior to adoptive transfer into WT C57BL/6 mice. Hemin-treated lymphocytes led to augmented OVA-specific cytotoxicity ( Figure 3I ). Our results indicate that the sole exposure of lymph node cells to hemin boosts 
microenvironment in governing the fate of tumor development. Considering the systemic changes in conditioned mice (Figures 4A-B) , we next evaluated whether hemin exerts an anti-tumor effect when injected at a site other than the flank subsequently challenged with the tumor cells. Similar to hemin conditioning on the ipsilateral flank, its administration on the contralateral flank also led to a significant increase in tumor latency (45±5 days in control mice, n=8; 56±3 days in ipsilateral conditioned animals, n=10; and 55±2 days in the contralateral-conditioned group, n=5; Figure 4E ). No significant differences were found between both conditioning strategies in terms of tumor latency, suggesting both treatments had a similar anti-tumor effect. Furthermore, in an effort to elucidate the relative contribution of the vascular and immune compartments, we tested if hemin conditioning was able to modulate tumor development in athymic nude mice. Tumor latency and growth did not significantly differ when comparing hemin-conditioned animals with control mice (Figure 4F) , confirming that the immune system is required to target PCa tumors in our experimental model.
Bioinformatic analysis of human prostate adenocarcinoma microarray datasets
To address potential clinical implications of elevated HO-1 expression in human prostate tumor samples, we searched the microarray database Oncomine (26) . We found 16 gene expression microarray datasets comparing prostate adenocarcinoma versus normal prostate tissue that met our eligibility criteria (Table S2) . Only 4 datasets presented increased expression for HMOX1 mRNA with P<0.05 ( Table 1) , in which only one of these datasets showed fold induction greater than 1.5. These results support the idea that HO-1 expression is not associated to prostate carcinogenesis. Given the small P-values obtained for these 4 datasets (n=122, n=112, n=150, n=19; refer to Table S2), we extended our analysis to assess the expression levels for LGALS1. Figure S3 ). We assessed in these same datasets the expression Figure S3) . On the contrary, these datasets with increased expression of HMOX1 also exhibited VCAM1, CD28, CD80 and CD86 upregulation in prostate adenocarcinoma compared with the normal gland (Table 1 and Figure S3) .
Interestingly, more intense lymphocyte infiltration was observed in tumors with elevated VCAM-1 (34).
Furthermore, CD28, CD80 and CD86 constitute key co-stimulatory molecules required to mount an effective immune response, and their elevated expression levels are indicative of T-cell activation.
These results support the aforementioned findings and point towards a subset of patients who might respond to anti-angiogenic and/or immune stimulatory therapy.
Histological analysis of HO-1 and Gal-1 in human PCa patient-derived xenografts
To further understand potential clinical implications, we screened a TMA containing 50 PDXs, each 
Discussion
Carcinogenesis is a multi-step process encompassing mechanisms in both the epithelial cell and the surrounding tissue. Numerous signaling pathways are involved in the dynamic crosstalk between these compartments, and their deregulation influences disease initiation, progression and patient prognosis (2) . Novel experimental strategies have been designed to re-educate the microenvironment in order to shift the balance towards an anti-tumorigenic profile (4). Here we designed an experimental protocol using a murine model to shape the niche where prostate tumor cells are subsequently implanted (Figure 1) . We demonstrate for the first time that hemin conditioning remodels the bidirectional interactions between the tumor and the surrounding tissue, affects tumor neo-vascularization and immune function and impairs tumor growth. Our results indicate that hemin conditioning acts, at least in part, through the inhibition of angiogenesis and the potentiation of tumor immunity, thus restraining PCa development. Our findings also demonstrate that hemin modulated tumor development when injected on the contralateral flank ( Figure 4E ). This strategy led to an increase in tumor latency that was comparable to that corresponding to ipsilateral hemin conditioning, further supporting potential novel therapeutic avenues for PCa. Of note, hemin is approved for use in treatments against acute intermittent porphyria.
Angiogenesis is essential for tumor development given that proliferation of cancer cells, as well as their metastatic spread rely on an adequate supply of both oxygen and nutrients and the removal of waste products. We demonstrate that hemin conditioning inhibits tumor-associated neo-vascularization in vitro and in vivo (Figures 2 and 4) . Hemin pre-treatment of HUVEC dramatically hindered tubulogenesis only in the presence of tumor CM, suggesting hemin-treated HUVEC are refractory to pro-angiogenic tumor-derived factors. We also found that hemin conditioning limits the tumor angiogenic process in vivo. We have previously documented the anti-angiogenic properties of HO-1 induction in the PCa epithelial compartment (15) . Moreover, this anti-angiogenic effect was also demonstrated in pancreatic cancer by exogenous administration of the HO-1 metabolic product CO (35) . In line with these observations, Ahmad et al (36) recently reported that CO exposure inhibits VEGF-induced endothelial cell proliferation, migration and capillary-like tube formation. Furthermore, in our pre-clinical model we found that Gal-1 expression was significantly reduced in tumors generated in hemin-treated mice. Our previous findings have shown that this lectin is highly expressed and regulated in the PCa microenvironment and plays a major role in PCa neovascularization (23). Notably, Croci et al (25, 37) elegantly demonstrated the existence of a glycosylation-based circuit in which Gal-1 interaction with VEGFR2 mimics VEGF-A function and induces angiogenesis. Here we confirmed that Gal-1 promotes the formation of tube-like structures in vitro. Strikingly, hemin treatment sensitized endothelial cells to apoptosis in a Gal-1-dependent dose (Figure 2) . It has been previously reported that endothelial cells may undergo Gal-1-induced apoptosis when a potential co-receptor for VEGFR-2, CD146, is downregulated (29, 30) ; in this regard, we have indeed confirmed that hemin treatment upon endothelial cells inhibits CD146 expression. Moreover, taking into consideration the prolonged inhibition of Gal-1 expression in tumors evidencing impaired growth, our data might indicate that hemin conditioning remodels the endothelial compartment, affecting its interaction with the tumor cell. However, other studies have reported pro-angiogenic roles for HO-1 and its metabolic products in different cancer models and other pathologies (reviewed in 12,38), providing evidence of the inconsistent function of HO-1 in tumorigenesis and unveiling the complexity of the angiogenic process. Thus, the role of this protein is far from clear, but the general consensus of opinion is that its effect is highly dependent on tumor type, the trigger of tissue-specific signaling pathways, and the relative contribution of the enzymatic products and the non-canonical roles.
Nevertheless, simultaneous targeting of multiple components of the tumor microenvironment will be required to achieve a durable and efficient anti-tumor response. Our results indicate that hemin conditioning can also boost the immune response (Figures 3 and 4) . Hemin treatment resulted in enhanced CD8 + T-cell proliferation and degranulation but, more importantly, we have provided strong evidence that subcutaneous administration of this agent augments in vivo antigen-specific cytotoxicity.
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challenge, as no significant differences were found. Although immunodeficient mice provide valuable information in cancer research, our findings add to cumulative data in literature that urge for fully immunocompetent and syngeneic animal models.
Finally, to assess the potential clinical implications of both HO-1 and Gal-1 in PCa, we searched the cancer database Oncomine. Interestingly, a subset of patients displays mild up-regulation of HO-1 with significantly lower expression for Gal-1, when comparing prostate adenocarcinoma vs. normal gland ( Table 1 and Figure S3 ). This was further evidenced by the analysis of PDXs, which also showcased a subgroup with mild HO-1 and low Gal-1 expression ( Table 2) . This subpopulation could potentially be more susceptible to hemin treatment as an adjuvant therapy, maintaining Gal-1 expression levels severely low and, in combination with other anti-angiogenic and/or immune therapies, might interrupt tumor growth and/or spread.
To summarize, our work provides evidence of the effect of hemin conditioning in both vascular and immune compartments, and its implications on PCa development. Our strategy was conceived to remodel the environment to counteract the effects of tumor-escape mechanisms. We speculate that novel therapeutic interventions should be designed to specifically target the reactive stroma. As mentioned above, we have previously shown that hemin treatment in prostate cancer cell lines does not have toxic effects and it even impairs proliferation, migration and invasion in vitro and HO-1 overexpression leads to smaller and less vascularized tumors in vivo (14, 15) . It should be noted that there is a considerable number of reports showcasing the pro-tumor role of HO-1 in different types of cancer, even in PCa (20, 21) . Consequently, further study should be carried out to elucidate the HO-1 function in cancer development. We are currently developing new experimental strategies to assess hemin effects on prostate tumor progression in vivo, including intratumor injections and other means of specifically targeting immune and endothelial cells infiltrating the tumor. The results from this paper provide a solid proof of concept to move forwards in this direction. over-expressed).
on May Cells were stimulated in the presence or absence of hemin (12h; 75μM) and stained for extracellular CD107a. D-E, lymph node cells were co-cultured with T-C1 cells for 24h in an anti-CD3-coated well (1µg/ml). Hemin (18.75, 37.5 and 75μM) was then added and proliferation was measured after 72h as previously described. Alternatively, degranulation was measured after 12h as previously described. 
